» Articles » PMID: 36508191

C5aR1 Shapes a Non-inflammatory Tumor Microenvironment and Mediates Immune Evasion in Gastric Cancer

Overview
Journal Biomol Biomed
Date 2022 Dec 12
PMID 36508191
Authors
Affiliations
Soon will be listed here.
Abstract

C5a receptor 1 (C5aR1) is associated with various inflammatory processes, the pathogenesis of immune diseases, and tumor growth. However, its role in the tumor microenvironment of gastric cancer (GC) remains unclear. In this study, the expression of C5aR1 in GC and normal gastric mucosa tissues was compared using data retrieved from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases, and the results were validated by in vitro qRT-PCR and immunohistochemical analyses. The relationship between C5aR1 expression and the overall survival of patients with GC was analyzed using the Kaplan-Meier method. Subsequently, enrichment analysis was performed, and the signaling pathways were screened. C5aR1 expression was also correlated with genes related to the immune checkpoint and immune cell infiltration. The results revealed that C5aR1 expression was enhanced in GC tissues compared to normal gastric tissues, and that patients with high expression of C5aR1 had a worse 10-year overall survival compared to those showing low expression of C5aR1. Functional analysis revealed that C5aR1 is a gene related to theimmune system and may play a crucial role in inflammatory and tumor immune responses. Additionally, C5aR1 showed a positive correlation with most immune checkpoint-related genes and a negative correlation with natural killer cells, dendritic cells, and CD8+ T cells. Immune evasion risk was observed to be significantly greater in patients with higher expression of C5aR1 than in those with lower expression. The results of this study reveal that C5aR1 shapes a non-inflammatory tumor microenvironment in GC and mediates immune evasion.

Citing Articles

The role of the C5a-C5aR pathway in iron metabolism and gastric cancer progression.

Ni Q, Yang H, Rao H, Zhang L, Xiong M, Han X Front Immunol. 2025; 15():1522181.

PMID: 39850877 PMC: 11754390. DOI: 10.3389/fimmu.2024.1522181.

References
1.
Vinay D, Ryan E, Pawelec G, Talib W, Stagg J, Elkord E . Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015; 35 Suppl:S185-S198. DOI: 10.1016/j.semcancer.2015.03.004. View

2.
Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

3.
Ricci A, Rizzo A, Llimpe F, Di Fabio F, de Biase D, Rihawi K . Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?. Cancers (Basel). 2021; 13(7). PMC: 8036476. DOI: 10.3390/cancers13071664. View

4.
Piao C, Zhang W, Li T, Zhang C, Qiu S, Liu Y . Complement 5a stimulates macrophage polarization and contributes to tumor metastases of colon cancer. Exp Cell Res. 2018; 366(2):127-138. DOI: 10.1016/j.yexcr.2018.03.009. View

5.
Zha H, Han X, Zhu Y, Yang F, Li Y, Li Q . Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade. Oncoimmunology. 2017; 6(10):e1349587. PMC: 5665063. DOI: 10.1080/2162402X.2017.1349587. View